125 related articles for article (PubMed ID: 8616707)
1. The cost of treating Gaucher disease.
Beutler E
Nat Med; 1996 May; 2(5):523-4. PubMed ID: 8616707
[No Abstract] [Full Text] [Related]
2. [Cost reduction in the treatment of Gaucher s disease].
García Salom P; Acedo A
Farm Hosp; 2007; 31(3):194-5. PubMed ID: 17941761
[No Abstract] [Full Text] [Related]
3. Drug development. Orphan drug windfalls?
Gershon D
Nature; 1992 Jan; 355(6359):381. PubMed ID: 1734267
[No Abstract] [Full Text] [Related]
4. Enzyme replacement in Gaucher disease.
Beutler E
PLoS Med; 2004 Nov; 1(2):e21. PubMed ID: 15578103
[TBL] [Abstract][Full Text] [Related]
5. Imiglucerase in the treatment of Gaucher disease: a history and perspective.
Deegan PB; Cox TM
Drug Des Devel Ther; 2012; 6():81-106. PubMed ID: 22563238
[TBL] [Abstract][Full Text] [Related]
6. Dosage-response in the treatment of Gaucher disease by enzyme replacement therapy.
Beutler E
Blood Cells Mol Dis; 2000 Aug; 26(4):303-6. PubMed ID: 11042031
[No Abstract] [Full Text] [Related]
7. Alglucerase: the debate continues.
Push S
Pharmacoeconomics; 1995 Mar; 7(3):268-9. PubMed ID: 10155316
[No Abstract] [Full Text] [Related]
8. [Financing of enzyme treatment in Gaucher disease].
Wisløff F
Tidsskr Nor Laegeforen; 2003 Feb; 123(3):364. PubMed ID: 12640908
[No Abstract] [Full Text] [Related]
9. Cost-effectiveness controversy.
Cox TM
Pharmacoeconomics; 1995 Jul; 8(1):82-3. PubMed ID: 10155604
[No Abstract] [Full Text] [Related]
10. Treatment regimens in Gaucher's disease.
Beutler E
Lancet; 1995 Aug; 346(8974):581-2. PubMed ID: 7658807
[No Abstract] [Full Text] [Related]
11. Low-dose versus high-dose therapy for Gaucher disease: Goals and markers.
Hollak CE; de Fost M; Aerts JM; vom Dahl S
Blood; 2007 Jan; 109(1):387; author reply 387-8. PubMed ID: 17190857
[No Abstract] [Full Text] [Related]
12. Consensus recommendations.
Beutler E
Br J Haematol; 2007 Sep; 138(6):673-5. PubMed ID: 17655726
[No Abstract] [Full Text] [Related]
13. Taliglucerase alfa approved for Gaucher disease.
Traynor K
Am J Health Syst Pharm; 2012 Jun; 69(12):1009. PubMed ID: 22644968
[No Abstract] [Full Text] [Related]
14. From the Food and Drug Administration.
Nightingale SL
JAMA; 1991 Jun; 265(22):2934. PubMed ID: 1903461
[No Abstract] [Full Text] [Related]
15. Low-dose versus high-frequency regimens in Gaucher's disease.
Maródi L
Lancet; 1995 Nov; 346(8987):1434. PubMed ID: 7475855
[No Abstract] [Full Text] [Related]
16. Gaucher disease with pulmonary involvement in a 6-year-old girl: report of resolution of radiographic abnormalities on increasing dose of imiglucerase.
Lee SY; Mak AW; Huen KF; Lam ST; Chow CB
J Pediatr; 2001 Dec; 139(6):862-4. PubMed ID: 11743514
[TBL] [Abstract][Full Text] [Related]
17. [Gaucher disease].
Iversen PO; Wisløff F
Tidsskr Nor Laegeforen; 2003 Feb; 123(3):304-7. PubMed ID: 12640894
[No Abstract] [Full Text] [Related]
18. No justification for very high-dose enzyme therapy for patients with type III Gaucher disease.
Zimran A; Elstein D
J Inherit Metab Dis; 2007 Nov; 30(6):843-4. PubMed ID: 18008181
[No Abstract] [Full Text] [Related]
19. Enzyme therapy for the treatment of type 1 Gaucher disease: clinical outcomes and dose - response relationships.
Hollak CE; de Fost M; van Dussen L; Vom Dahl S; Aerts JM
Expert Opin Pharmacother; 2009 Nov; 10(16):2641-52. PubMed ID: 19743939
[TBL] [Abstract][Full Text] [Related]
20. Why Genzyme can charge so much for Cerezyme.
Anand G
Wall St J (East Ed); 2005 Nov; ():A15. PubMed ID: 16502533
[No Abstract] [Full Text] [Related]
[Next] [New Search]
